Study guide
11.1 Pharmacokinetics & Pharmacodynamics
MRCPI in General Medicine Part I Written
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Strategy & Foundation
1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy
2 Chapter 2: Cardiology & Vascular Medicine
2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases
3 Chapter 3: Respiratory Medicine
3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea
4 Chapter 4: Gastroenterology & Hepatology
4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition
5 Chapter 5: Nephrology & Acid-Base Disorders
5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders
6 Chapter 6: Endocrinology & Diabetes
6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes
7 Chapter 7: Rheumatology & Clinical Immunology
7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology
8 Chapter 8: Haematology & Medical Oncology
8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies
9 Chapter 9: Neurology & Dermatology
9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease
10 Chapter 10: Acute Medicine, Critical Care & Geriatrics
10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care
11 Chapter 11: Clinical Pharmacology & Therapeutics
11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety
12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics
12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics
11.1 Pharmacokinetics & Pharmacodynamics
Key Takeaways Explain This Topic AI
Steady-state plasma concentration (Css) is achieved after 4 to 5 elimination half-lives (t1/2), independent of dosing rate or administration route.
The loading dose equation LD = (Ctarget x Vd) / F depends on Volume of Distribution (Vd), which for digoxin is ~7 L/kg, requiring major dose reduction in elderly patients and renal impairment.
Phenytoin exhibits zero-order (capacity-limited) kinetics at therapeutic concentrations (10–20 mg/L); small dose increments can lead to disproportionate serum level increases and severe neurotoxicity.
Co-administration of potent CYP3A4/CYP2C9 inducers (e.g., rifampicin, carbamazepine, phenytoin) accelerates substrate clearance over 1–2 weeks, whereas CYP inhibitors (e.g., clarithromycin, amiodarone, ketoconazole) rapidly increase substrate concentrations.
Therapeutic Drug Monitoring (TDM) targets include vancomycin trough 15–20 mg/L for severe MRSA, gentamicin once-daily trough <1 mg/L, and lithium therapeutic range 0.6–1.0 mmol/L.
Last updated: July 2026
Principles of Pharmacokinetics (ADME)
Pharmacokinetics evaluates the quantitative timeline of drug movement through the human body. Mastering absorption, distribution, metabolism, and elimination (ADME) allows clinicians to individualize therapy, calculate loading and maintenance doses, and anticipate therapeutic failure or drug toxicity in medical inpatients.
Absorption and Bioavailability ( F F F )
Bioavailability ( F F F ) represents the fraction of an administered drug dose that reaches the systemic circulation in active, unchanged form. Intravenous (IV) administration delivers 100 % 100\% 100% bioavailability ( F = 1.0 F = 1.0 F = 1.0 ). For oral formulations, F F F is limited by incomplete intestinal absorption and first-pass hepatic metabolism .
High first-pass metabolism : Drugs like propranolol ( F ≈ 26 % F \approx 26\% F ≈ 26% ), morphine ( F ≈ 30 % F \approx 30\% F ≈ 30% ), lidocaine ( F < 3 % F < 3\% F < 3% ), and verapamil ( F ≈ 20 % F \approx 20\% F ≈ 20% ) undergo extensive presystemic degradation by intestinal mucosal and hepatic CYP3A4 enzymes and P-glycoprotein (P-gp/MDR1) efflux transporters. Consequently, oral doses of morphine or propranolol are significantly higher than equivalent IV doses.
Factors altering absorption : Gastrointestinal motility, gastric pH (e.g., co-administration of proton pump inhibitors reducing ketoconazole absorption), mucosal edema in congestive heart failure, and enteral feeding interactions (e.g., tube feeds binding oral phenytoin).
Volume of Distribution ( V d V_d V d )
Volume of Distribution ( V d V_d V d ) is a hypothetical fluid volume required to contain the total body content of a drug at the same concentration as present in vascular plasma: V d = Total amount of drug in body ( D ) Plasma concentration ( C ) V_d = \frac{\text{Total amount of drug in body } (D)}{\text{Plasma concentration } (C)} V d = Plasma concentration ( C ) Total amount of drug in body ( D )
The magnitude of V d V_d V d provides crucial insights into anatomical drug distribution:
Low V d V_d V d ( < 0.2 L/kg < 0.2 \text{ L/kg} < 0.2 L/kg or 14 L 14 \text{ L} 14 L in a 70 kg 70 \text{ kg} 70 kg adult) : Confined predominantly to the vascular space or extracellular fluid. Highly plasma protein-bound or large hydrophilic molecules exhibit low V d V_d V d (e.g., warfarin 0.14 L/kg 0.14 \text{ L/kg} 0.14 L/kg , unfractionated heparin, gentamicin, aspirin).
High V d V_d V d ( > 1 L/kg > 1 \text{ L/kg} > 1 L/kg or > 70 L > 70 \text{ L} > 70 L ) : Extensively distributed into peripheral tissues, fat, or skeletal muscle. Lipophilic or tissue-bound drugs demonstrate massive V d V_d V d (e.g., digoxin ≈ 7 L/kg \approx 7 \text{ L/kg} ≈ 7 L/kg , chloroquine > 100 L/kg > 100 \text{ L/kg} > 100 L/kg , tricyclic antidepressants). Hemodialysis is ineffective for removing drugs with high V d V_d V d .
Metabolism: Phase I and Phase II Reactions
Hepatic drug clearance involves two main enzymatic processes:
Phase I Reactions (Functionalization) : Oxidation, reduction, and hydrolysis reactions primarily mediated by the Cytochrome P450 (CYP450) monooxygenase superfamily situated in smooth endoplasmic reticulum. Phase I converts lipophilic compounds into more polar metabolites.
CYP3A4 : Metabolizes > 50 % >50\% > 50% of prescribed drugs (statins, calcium channel blockers, immunosuppressants).
CYP2D6 : Polymorphic enzyme (poor vs ultra-rapid metabolizers); processes codeine, tamoxifen, beta-blockers, and SSRIs.
CYP2C9/2C19 : Metabolizes warfarin, phenytoin, omeprazole, and clopidogrel.
Phase II Reactions (Conjugation) : Covalent attachment of polar endogenous groups (glucuronide, sulfate, acetate, glutathione) to produce hydrophilic, inactive conjugates excreted by kidneys or bile.
Acetylation (NAT2) : Genetic polymorphism determines slow vs. fast acetylator status. Slow acetylators receiving isoniazid, hydralazine, or procainamide face high risks of drug-induced lupus erythematosus and peripheral neuropathy.
Clinical Table: CYP450 Inducers and Inhibitors
Category High-Yield Agents Clinical Mechanism & Impact
Potent Inducers Rifampicin, Carbamazepine, Phenytoin, Phenobarbital, St John’s Wort, Chronic Alcohol, Griseofulvin Accelerates CYP expression over 7–14 days. Decreases plasma levels of warfarin, DOACs, OCPs, tacrolimus, leading to therapeutic failure.
Potent Inhibitors Sodium valproate, Isoniazid, Cimetidine, Ketoconazole/Azoles, Fluoxetine/SSRIs, Erythromycin/Clarithromycin, Diltiazem/Verapamil, Grapefruit juice, Amiodarone, Ciprofloxacin Immediately blocks CYP catalytic sites. Increases plasma levels of statins, digoxin, warfarin, theophylline, precipitating acute drug toxicity.
Elimination Kinetics: First-Order vs. Zero-Order
Drug elimination occurs through hepatic metabolism, renal excretion, or biliary elimination.
First-Order Kinetics (Linear Elimination)
Mechanism : A constant fraction (percentage) of drug is eliminated per unit time. The rate of elimination ( V e V_e V e ) is directly proportional to plasma concentration ( C C C ).
Half-life ( t 1 / 2 t_{1/2} t 1/2 ) : Constant and independent of dose.
Steady-State ( C s s C_{ss} C ss ) : Achieved when the rate of drug administration equals the rate of elimination. Reaching C s s C_{ss} C ss requires 4 to 5 half-lives .
Calculations : t 1 / 2 = 0.693 × V d C L and Loading Dose (LD) = C t a r g e t × V d F t_{1/2} = \frac{0.693 \times V_d}{CL} \quad \text{and} \quad \text{Loading Dose (LD)} = \frac{C_{target} \times V_d}{F} t 1/2 = C L 0.693 × V d and Loading Dose (LD) = F C t a r g e t × V d Maintenance Dose Rate = C s s × C L F \text{Maintenance Dose Rate} = \frac{C_{ss} \times CL}{F} Maintenance Dose Rate = F C ss × C L
Zero-Order Kinetics (Non-linear / Capacity-Limited Elimination)
Mechanism : Metabolic clearance pathways become saturated at therapeutic plasma concentrations (Michaelis-Menten kinetics). A constant amount (mass) of drug is eliminated per unit time, regardless of concentration.
Half-life ( t 1 / 2 t_{1/2} t 1/2 ) : Variable; half-life increases as dose increases.
Clinical Risk : Dose increases produce unpredictable, non-linear, exponential jumps in plasma drug levels.
Classic Zero-Order Drugs : Phenytoin (saturates near therapeutic levels of 10–20 mg/L), Ethanol, High-dose Aspirin (salicylates), and Theophylline.
Pharmacodynamics: Receptor Kinetics and Efficacy
Pharmacodynamics examines the biochemical and physiological effects of drugs on target receptors.
Full Agonist : Binds receptor, induces maximal conformational change, and achieves maximal efficacy ( E m a x = 100 % E_{max} = 100\% E ma x = 100% ).
Partial Agonist : Binds receptor with lower intrinsic activity ( E m a x < 100 % E_{max} < 100\% E ma x < 100% ), functioning as a competitive antagonist in the presence of full agonists (e.g., buprenorphine at μ \mu μ -opioid receptors, pindolol in adrenergic receptors).
Competitive Antagonist : Competitively binds the active site. Shifts dose-response curve to the right (increases E C 50 EC_{50} E C 50 , potency decreases), but E m a x E_{max} E ma x remains achievable with higher agonist concentrations.
Non-Competitive Antagonist : Binds allosteric site or irreversibly covalently binds active site. Reduces maximal response ( E m a x E_{max} E ma x decreases), while E C 50 EC_{50} E C 50 remains unchanged.
Therapeutic Drug Monitoring (TDM) Targets
Drugs with narrow therapeutic indices ( T I = T D 50 / E D 50 TI = TD_{50} / ED_{50} T I = T D 50 / E D 50 ) demand routine serum concentration monitoring to balance efficacy against severe toxicity.
Clinical Table: Therapeutic Drug Monitoring Targets & Toxicity Features
Drug Target Therapeutic Window Sampling Time Clinical Toxicity Features
Digoxin 0.5–0.9 mcg/L (HF); 0.8–2.0 mcg/L (AF) ≥ 6 hours \ge 6 \text{ hours} ≥ 6 hours post-dose Nausea, xanthopsia (yellow-green vision), Mobitz Type I/II AV block, ventricular bigeminy. Toxicity exacerbated by hypokalemia, hypomagnesemia, hypercalcemia.
Gentamicin Once-daily: Trough < 1 mg/L < 1 \text{ mg/L} < 1 mg/L at 18–24h; Multiple daily: Peak 5–10 mg/L, Trough < 2 mg/L < 2 \text{ mg/L} < 2 mg/L Trough immediately pre-dose; Peak 30 min post-infusion Vestibulo-ototoxicity (irreversible bilateral hair cell loss), acute tubular necrosis (ATN, non-oliguric AKI).
Vancomycin Trough 15–20 mg/L (severe infection/MRSA endocarditis); 10–15 mg/L (uncomplicated SSTI) Trough within 30 min prior to 4th dose Nephrotoxicity, ototoxicity, Red Man Syndrome (histamine release from rapid infusion).
Lithium 0.6–1.0 mmol/L (maintenance); 0.8–1.2 mmol/L (acute mania) 12 hours post-dose (trough) Coarse tremor, ataxia, dysarthria, seizures, nephrogenic diabetes insipidus. Toxicity triggered by dehydration, NSAIDs, ACE inhibitors, thiazides.
Phenytoin 10–20 mg/L (total); 1–2 mg/L (free unbound) Trough prior to dose Nystagmus ( > 20 mg/L >20 \text{ mg/L} > 20 mg/L ), ataxia ( > 30 mg/L >30 \text{ mg/L} > 30 mg/L ), lethargy/encephalopathy ( > 40 mg/L >40 \text{ mg/L} > 40 mg/L ), gingival hyperplasia, peripheral neuropathy.
Theophylline 10–20 mg/L Trough prior to dose Refractory seizures, fatal ventricular tachyarrhythmias, intractable vomiting.
Exam Pearls
MRCPI Exam Pearl : Hypokalemia does not alter serum digoxin concentration, but it markedly increases myocardial sensitivity to digoxin by diminishing extracellular potassium competition for the N a + / K + Na^+/K^+ N a + / K + -ATPase alpha subunit. Always check and correct potassium ( K + ≥ 4.0 mmol/L K^+ \ge 4.0 \text{ mmol/L} K + ≥ 4.0 mmol/L ) in suspected digoxin toxicity.
MRCPI Exam Pearl : Thiazide diuretics reduce renal clearance of lithium by 24 − 40 % 24-40\% 24 − 40% because compensatory proximal tubular sodium reabsorption in response to distal natriuresis leads to co-reabsorption of filtered lithium.